Bevacizumab targeted therapy is usually administered every 2 or 3 weeks. Bevacizumab is a humanized monoclonal antibody in genetically engineered cells that blocks vascular endothelial growth factor activity and can be combined with chemotherapy. It is mainly indicated for colorectal cancer, breast cancer, and non-squamous non-small cell carcinoma. Recommended Use: Use every 2 weeks or every 3 weeks. In addition, bevacizumab should be applied at least 4 weeks apart after surgery. In addition, the main toxic side effects of bevacizumab are gastrointestinal perforation, thromboembolism, hypertension, proteinuria, bleeding, fatigue, and abdominal pain. Bevacizumab is contraindicated for those who are allergic to it. Therefore, it is important to use it under the guidance of a doctor, and not to use it privately, so as not to cause unnecessary damage.